Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara
NCT01556308 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6
Last updated 2014-07-29
Summary
Introduction: Epidermolysis Bullosa Simplex-Dowling-Meara (DM-EBS) is a rare genodermatosis characterized by spontaneous or post traumatic large cutaneous blisters. No curative treatment is actually available. Some data suggest a role of inflammation in the occurrence of blisters. The aim of this study is to study the epidermis inflammatory mechanisms in DM-EBS.
Material and methods: A first retrospective immunohistochemical study will be led on remainder skin biopsies of DM-EBS patients took for the diagnosis. A second clinical multicentric prospective study will be led on 8 patients older than 1 year with severe DM-EBS. After informed written consent, they will answer to a standardized questionnaire. In case of flare of the disease, the liquid and the top of the blisters will be took. Samples will be analyzed in the Pr Nicolas 851 INSERM unit. After centrifugation of the liquid blisters, the repartition of inflammatory cells will be evaluated by Fluorescence Activated Cell Sorting on the pellet. Markers of inflammation will be evaluated on the surnageant with Luminex® technical with a multiplex targeting cytokines and chemokines. An immuno-histochemic analysis in association with a quantitative PCR will be made on the top of the blisters. If unknown, genotypic study will be made.
Perspectives: A better comprehension of physiopathological mechanisms in DM-EBS could offer new therapeutic ways.
Conditions
- Epidermolysis Bullosa Simplex Dowling Meara
Interventions
- PROCEDURE
-
Taking of liquid and top of blisters
the liquid and the top of blisters will be took.
Sponsors & Collaborators
-
Centre Hospitalier Universitaire de Nice
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 1 Year
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-03-31
- Primary Completion
- 2012-03-31
- Completion
- 2013-10-31
Countries
- France
Study Locations
More Related Trials
-
Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)
NCT04757727 ·Status: COMPLETED
-
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
NCT02960997 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Evolution of Body and Scalp Skin Discomfort in Patients With Hereditary Ichthyosis After Wraps (EnvelopIchtyose)
NCT05979506 ·Status: RECRUITING ·Phase: NA
-
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
NCT03016715 ·Status: UNKNOWN ·Phase: PHASE2
-
Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis
NCT06213909 ·Status: RECRUITING
-
Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB
NCT02004600 ·Status: WITHDRAWN ·Phase: NA
-
Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa
NCT07230223 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
NCT03585946 ·Status: WITHDRAWN
-
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
NCT04213261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa
NCT03529877 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients
NCT02833909 ·Status: COMPLETED ·Phase: NA
-
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
NCT01019148 ·Status: RECRUITING
-
Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
NCT05732987 ·Status: RECRUITING
-
Diacerin for the Treatment of Epidermolysis Bullosa Simplex
NCT02470689 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
NCT01874769 ·Status: COMPLETED
-
Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
NCT00904163 ·Status: COMPLETED
-
Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa.
NCT05288478 ·Status: UNKNOWN ·Phase: PHASE2
-
Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa
NCT01908088 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
NCT06423573 ·Status: RECRUITING
-
A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
NCT04213703 ·Status: WITHDRAWN
-
ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
NCT02384460 ·Status: COMPLETED ·Phase: PHASE3
-
Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
NCT06167408 ·Status: COMPLETED
-
Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa
NCT01768026 ·Status: WITHDRAWN
-
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
NCT05838092 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT02588625 ·Status: WITHDRAWN ·Phase: PHASE2